NYSE:ZYME - Zymeworks Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.65 +0.30 (+2.09 %)
(As of 09/18/2018 11:43 AM ET)
Previous Close$14.49
Today's Range$14.25 - $14.65
52-Week Range$6.87 - $29.00
Volume1,841 shs
Average Volume87,631 shs
Market Capitalization$468.53 million
P/E Ratio-25.32
Dividend YieldN/A
Beta4.69
Zymeworks logoZymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Debt-to-Equity RatioN/A
Current Ratio7.26
Quick Ratio7.26

Price-To-Earnings

Trailing P/E Ratio-25.32
Forward P/E Ratio-6.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$51.76 million
Price / Sales9.05
Cash FlowN/A
Price / CashN/A
Book Value$4.59 per share
Price / Book3.19

Profitability

EPS (Most Recent Fiscal Year)($0.57)
Net Income$-10,400,000.00
Net Margins-14.66%
Return on Equity-8.83%
Return on Assets-7.62%

Miscellaneous

Employees147
Outstanding Shares31,960,000
Market Cap$468.53 million

Zymeworks (NYSE:ZYME) Frequently Asked Questions

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) released its quarterly earnings data on Wednesday, August, 1st. The company reported ($0.22) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.58) by $0.36. The business had revenue of $22 million for the quarter, compared to the consensus estimate of $22 million. Zymeworks had a negative net margin of 14.66% and a negative return on equity of 8.83%. View Zymeworks' Earnings History.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Zymeworks.

What price target have analysts set for ZYME?

7 brokers have issued 1 year price objectives for Zymeworks' shares. Their forecasts range from $15.00 to $37.00. On average, they anticipate Zymeworks' share price to reach $24.00 in the next year. This suggests a possible upside of 65.3% from the stock's current price. View Analyst Price Targets for Zymeworks.

What is the consensus analysts' recommendation for Zymeworks?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zymeworks.

Who are some of Zymeworks' key competitors?

Who are Zymeworks' key executives?

Zymeworks' management team includes the folowing people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 46)
  • Mr. Neil Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 46)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 55)
  • Dr. Donald L. Drakeman Ph.D., J.D., Special Advisor (Age 64)
  • Dr. Surjit Dixit, VP of Technology (Age 45)

When did Zymeworks IPO?

(ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Has Zymeworks been receiving favorable news coverage?

News articles about ZYME stock have trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zymeworks earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media headlines about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Zymeworks.

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (4.10%), Vivo Capital LLC (1.94%), Renaissance Technologies LLC (1.05%), Vident Investment Advisory LLC (0.48%), Wedge Capital Management L L P NC (0.46%) and Laurion Capital Management LP (0.34%). View Institutional Ownership Trends for Zymeworks.

Which major investors are buying Zymeworks stock?

ZYME stock was acquired by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Vivo Capital LLC, Renaissance Technologies LLC, Vident Investment Advisory LLC, Wedge Capital Management L L P NC, Laurion Capital Management LP, Point72 Asset Management L.P. and Millennium Management LLC. View Insider Buying and Selling for Zymeworks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $14.52.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $468.53 million and generates $51.76 million in revenue each year. The company earns $-10,400,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Zymeworks employs 147 workers across the globe.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]


MarketBeat Community Rating for Zymeworks (NYSE ZYME)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  213
MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel